Intellia Therapeutics Inc Stock
Intellia Therapeutics Inc took a tumble today and lost -€0.420 (-3.540%).
Our community is currently high on Intellia Therapeutics Inc with 28 Buy predictions and 7 Sell predictions.
Based on the current price of 11.4 € the target price of 25 € shows a potential of 119.3% for Intellia Therapeutics Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Intellia Therapeutics Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -3.540% | 1.064% | 0.176% | 52.733% | 46.042% | -71.378% | -80.789% |
| Chromadex Corp | -1.910% | 0.000% | 8.466% | -42.254% | -25.455% | 238.843% | -44.595% |
| Cardio3 Biosciences S.A. | -0.370% | 3.053% | -1.460% | -36.471% | 100.000% | -54.545% | -94.584% |
| Polynovo Ltd | -3.420% | 0.000% | 6.604% | -16.912% | -16.912% | -36.872% | -68.258% |
Comments
Intellia Therapeutics (NTLA) had its price target raised by Canaccord Genuity Group Inc. from $48.00 to $58.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its "outperform" rating reaffirmed by Citigroup Inc..
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its "sell" rating reaffirmed by The Goldman Sachs Group, Inc..
Show more
Ratings data for NTLA provided by MarketBeat
News
3 Biotech Stocks That Could Benefit from the Patent Cliff
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
A key reason for this activity is
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics (NASDAQ:
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood seems to always be making market moves. The founder and CEO of Ark Invest publishes her transactions at the end of every trading day, and that gives us all a great way to track one of